Insights into targeting LKB1 in tumorigenesis

Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391(6663):184–187.

Li C, Lyu J, Meng QH. MiR-93 promotes tumorigenesis and metastasis of non-small cell lung cancer cells by activating the PI3K/Akt pathway via inhibition of LKB1/PTEN/CDKN1A. J Cancer. 2017;8(5):870–879.

Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26(40):5911–5918.

Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One. 2009;4(4):e5137.

Pierce SE, Granja JM, Corces MR, et al. LKB1 inactivation modulates chromatin accessibility to drive metastatic progression. Nat Cell Biol. 2021;23(8):915–924.

McCarthy A, Lord CJ, Savage K, et al. Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J Pathol. 2009;219(3):306–316.

Collet L, Ghurburrun E, Meyers N, et al. Kras and Lkb1 mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells. Gut. 2020;69(4):704–714.

Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res. 2006;4(11):843–849.

Qiu B, Wei W, Zhu J, Fu G, Lu D. EMT induced by loss of LKB1 promotes migration and invasion of liver cancer cells through ZEB1-induced YAP signaling. Oncol Lett. 2018;16(5):6465–6471.

Liang X, Nan KJ, Li ZL, Xu QZ. Overexpression of the LKB1 gene inhibits lung carcinoma cell proliferation partly through degradation of c-myc protein. Oncol Rep. 2009;21(4):925–931.

Peart T, Ramos Valdes Y, Correa RJ, et al. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget. 2015;6(26):22424–22438.

Dahmani R, Just PA, Delay A, et al. A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties. Oncogene. 2015;34(18):2337–2346.

Lee SW, Li CF, Jin G, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell. 2015;57(6):1022–1033.

Hao B, Xiao Y, Song F, et al. Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16. Int J Mol Med. 2018;41(3):1365–1376.

Su CC, Hsieh KL, Liu PL, et al. AICAR induces apoptosis and inhibits migration and invasion in prostate cancer cells through an AMPK/mTOR-dependent pathway. Int J Mol Sci. 2019;20(7):1647.

Kong L, Zhang H, Lu C, et al. AICAR, an AMP-activated protein kinase activator, ameliorates acute pancreatitis-associated liver injury partially through Nrf2-mediated antioxidant effects and inhibition of NLRP3 inflammasome activation. Front Pharmacol. 2021;12:724514.

Moro M, Caiola E, Ganzinelli M, et al. Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018;13(11):1692–1704.

Gámez B, Morris EV, Olechnowicz SWZ, et al. The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo. Transl Oncol. 2022;15(1):101301.

Sid B, Glorieux C, Valenzuela M, et al. AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells. Biochem Pharmacol. 2014;91(2):168–180.

Yamaguchi S, Kaneko M, Narukawa M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin Transl Sci. 2021;14(3):1113–1122.

Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. N Engl J Med. 1949;241(26):1031–1036.

Foley TR, McGarrity TJ, Abt AB. Peutz-jeghers syndrome: a clinicopathologic survey of the "harrisburg family" with a 49-year follow-up. Gastroenterology. 1988;95(6):1535–1540.

Peutz JL. On a very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentations of skin and mucous membrane. Ned Tijdschr Geneeskd. 1921;10:134–146.

Dib C, Fauré S, Fizames C, et al. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996;380(6570):152–154.

Hemminki A, Tomlinson I, Markie D, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet. 1997;15(1):87–90.

Ylikorkala A, Avizienyte E, Tomlinson IP, et al. Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet. 1999;8(1):45–51.

Avizienyte E, Roth S, Loukola A, et al. Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res. 1998;58(10):2087–2090.

Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18(1):38–43.

Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett. 2003;546(1):159–165.

Klein D. Quantification using real-time PCR technology: applications and limitations. Trends Mol Med. 2002;8(6):257–260.

Olschwang S, Boisson C, Thomas G. Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma. J Med Genet. 2001;38(6):356–360.

Mehenni H, Blouin JL, Radhakrishna U, et al. Peutz-Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. Am J Hum Genet. 1997;61(6):1327–1334.

Ashley DJ. The two “hit” and multiple “hit” theories of carcinogenesis. Br J Cancer. 1969;23(2):313–328.

Tavusbay C, Acar T, Kar H, Atahan K, Kamer E. The patients with Peutz-Jeghers syndrome have a high risk of developing cancer. Turk J Surg. 2018;34(2):162–164.

Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999;154(6):1835–1840.

Lin C, Lin X, Lin K, Tan J, Wei C, Liu T. LKB1 expression and the prognosis of lung cancer: a meta-analysis. Medicine. 2021;100(46):e27841.

Kim CJ, Cho YG, Park JY, et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer. 2004;40(1):136–141.

Kenanli E, Karaman E, Enver O, Ulutin T, Buyru N. Genetic alterations of the LKB1 gene in head and neck cancer. DNA Cell Biol. 2010;29(12):735–738.

Miyaki M, Iijima T, Hosono K, et al. Somatic mutations of LKB1 and beta-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome. Cancer Res. 2000;60(22):6311–6313.

Nakanishi C, Yamaguchi T, Iijima T, et al. Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology. 2004;67(5–6):476–479.

Nguyen B, Fong C, Luthra A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185(3):563–575.e11.

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525.

Carretero J, Shimamura T, Rikova K, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010;17(6):547–559.

Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–1075.

Kottakis F, Nicolay BN, Roumane A, et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature. 2016;539(7629):390–395.

Caiola E, Falcetta F, Giordano S, et al. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018;37(1):302.

Papillon-Cavanagh S, Doshi P, Dobrin R, Szustakowski J, Walsh AM. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 2020;5(2):e000706.

Kitajima S, Ivanova E, Guo S, et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 2019;9(1):34–45.

Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13(22):2004–2008.

Bright NJ, Thornton C, Carling D. The regulation and function of mammalian AMPK-related kinases. Acta Physiol. 2009;196(1):15–26.

Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A. 2004;101(10):3329–3335.

Maillet V, Boussetta N, Leclerc J, et al. LKB1 as a gatekeeper of hepatocyte proliferation and genomic integrity during liver regeneration. Cell Rep. 2018;22(8):1994–2005.

Patel K, Foretz M, Marion A, et al. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat Commun. 2014;5:4535.

Shan T, Xiong Y, Kuang S. Deletion of Lkb1 in adult mice results in body weight reduction and lethality. Sci Rep. 2016;6:36561.

Barnes AP, Lilley BN, Pan YA, et al. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell. 2007;129(3):549–563.

Yamada E, Pessin JE, Kurland IJ, Schwartz GJ, Bastie CC. Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. Cell Metabol. 2010;11(2):113–124.

Tang HMV, Gao WW, Chan CP, et al. LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription. Retrovirology. 2013;10(1):40.

Wang YS, Chen J, Cui F, et al. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget. 2016;7(45):73389–73401.

Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell. 2001;7(6):1307–1319.

Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–575.

Carretero J, Medina PP, Blanco R, et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene. 2007;26(11):1616–1625.

Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008;412(2):211–221.

Feng Y, Yang J, Wang Y, et al. Cafestol inhibits colon cancer cell proliferation and tumor growth in xenograft mice by activating LKB1/AMPK/ULK1-dependent autophagy. J Nutr Biochem. 2024;129:109623.

Hou T, Wang Y, Dan W, et al. β-Ionone represses renal cell carcinoma progression through activating LKB1/AMPK-triggered autophagy. J Biochem Mol Toxicol. 2023;37(6):e23331.

Lin R, Elf S, Shan C, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015;17(11):1484–1496.

Ng TL, Leprivier G, Robertson MD, et al. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ. 2012;19(3):501–510.

Casimiro MC, Di Sante G, di Rocco A, et al. Cyclin D1 restrains oncogene-induced autophagy by regulating the AMPK-LKB1 signaling axis. Cancer Res. 2017;77(13):3391–3405.

Murray CW, Brady JJ, Tsai MK, et al. An LKB1-SIK axis suppresses lung tumor growth and controls differentiation. Cancer Discov. 2019;9(11):1590–1605.

Hollstein PE, Eichner LJ, Brun SN, et al. The AMPK-related kinases SIK₁ and SIK₃ mediate key tumor-suppressive effects of LKB1 in NSCLC. Cancer Discov. 2019;9(11):1606–1627.

Tarumoto Y, Lu B, Somerville TDD, et al. LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia. Mol Cell. 2018;69(6):1017–1027.e6.

Zagórska A, Deak M, Campbell DG, et al. New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion. Sci Signal. 2010;3(115):ra25.

Whyte D, Skalka G, Walsh P, et al. NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Mol Oncol. 2023;17(7):1212–1227.

Machino H, Kaneko S, Komatsu M, et al. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Commun Biol. 2022;5(1):39.

Rines AK, Burke MA, Fernandez RP, Volpert OV, Ardehali H. Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of β-catenin. Faseb J. 2012;26(11):4685–4695.

Fukuyama M, Sakuma K, Park R, et al. C. elegans AMPKs promote survival and arrest germline development during nutrient stress. Biol Open. 2012;1(10):929–936.

Bland ML, Lee RJ, Magallanes JM, Foskett JK, Birnbaum MJ. AMPK supports growth in Drosophila by regulating muscle activity and nutrient uptake in the gut. Dev Biol. 2010;344(1):293–303.

Ikeda Y, Sato K, Pimentel DR, et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem. 2009;284(51):35839–35849.

Fu A, Robitaille K, Faubert B, et al. LKB1 couples glucose metabolism to insulin secretion in mice. Diabetologia. 2015;58(7):1513–1522.

Thomson DM, Porter BB, Tall JH, Kim HJ, Barrow JR, Winder WW. Skeletal muscle and heart LKB1 deficiency causes decreased voluntary running and reduced muscle mitochondrial marker enzyme expression in mice. Am J Physiol Endocrinol Metab. 2007;292(1):E196–E202.

Han SH, Malaga-Dieguez L, Chinga F, et al. Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism. J Am Soc Nephrol. 2016;27(2):439–453.

Xu Y, Gao Y, Huang Z, et al. LKB1 suppresses androgen synthesis in a mouse model of hyperandrogenism via IGF-1 signaling. FEBS Open Bio. 2019;9(10):1817–1825.

George SH, Milea A, Sowamber R, Chehade R, Tone A, Shaw PA. Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. Oncogene. 2016;35(1):59–68.

Li N, Wang Y, Neri S, et al. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun. 2019;10(1):4363.

Contreras CM, Akbay EA, Gallardo TD, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech. 2010;3(3–4):181–193.

Tanwar PS, Kaneko-Tarui T, Zhang L, Teixeira JM. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. Hum Mol Genet. 2012;21(20):4394–4405.

Asada N, Sanada K, Fukada Y. LKB1 regulates neuronal migration and neuronal differentiation in the developing neocortex through centrosomal positioning. J Neurosci. 2007;27(43):11769–11775.

Men Y, Zhang A, Li H, et al. LKB1 regulates cerebellar development by controlling sonic hedgehog-mediated granule cell precursor proliferation and granule cell migration. Sci Rep. 2015;5:16232.

Asada N, Sanada K. LKB1-mediated spatial control of GSK3 and adenomatous polyposis coli contributes to centrosomal forward movement and neuronal migration in the developing neocortex. J Neurosci. 2010;30(26):8852–8865.

Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009;16(2):256–270.

Williams T, Courchet J, Viollet B, Brenman JE, Polleux F. AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress. Proc Natl Acad Sci USA. 2011;108(14):5849–5854.

Claret M, Smith MA, Knauf C, et al. Deletion of Lkb1 in pro-opiomelanocortin neurons impairs peripheral glucose homeostasis in mice. Diabetes. 2011;60(3):735–745.

McClatchy DB, Ma Y, Liu C, et al. Pulsed azidohomoalanine labeling in mammals (PALM) detects changes in liver-specific LKB1 knockout mice. J Proteome Res. 2015;14(11):4815–4822.

Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646.

Sakamoto K, McCarthy A, Smith D, et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 2005;24(10):1810–1820.

Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabol. 2011;13(4):376–388.

Li C, Dong X, Du W, et al. LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis. Signal Transduct Targeted Ther. 2020;5(1):187.

Mans LA, Querol Cano L, van Pelt J, Giardoglou P, Keune WJ, Haramis AG. The tumor suppressor LKB1 regulates starvation-induced autophagy under systemic metabolic stress. Sci Rep. 2017;7(1):7327.

Hezel AF, Gurumurthy S, Granot Z, et al. Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol. 2008;28(7):2414–2425.

Han Y, Feng H, Sun J, et al. Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. J Clin Investig. 2019;129(5):1895–1909.

Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M, Taketo MM. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res. 2002;62(16):4549–4553.

Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One. 2011;6(1):e16209.

Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 2008;68(7):2223–2232.

Kou B, Kou Q, Ma B, et al. Thymoquinone inhibits metastatic phenotype and epithelial-mesenchymal transition in renal cell carcinoma by regulating the LKB1/AMPK signaling pathway. Oncol Rep. 2018;40(3):1443–1450.

Wang L, Li H, Zhen Z, et al. CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma. Gene. 2019;690:129–136.

Kan JY, Yen MC, Wang JY, et al. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget. 2016;7(21):31336–31349.

Li NS, Zou JR, Lin H, et al. LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells. Tumour Biol. 2016;37(6):8249–8258.

Li J, Liu J, Li P, et al. Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. J Exp Clin Cancer Res. 2014;33(1):70.

Zheng X, Chi J, Zhi J, et al. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration. Oncogene. 2018;37(4):502–511.

Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448(7155):807–810.

Han X, Li F, Fang Z, et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun. 2014;5:3261.

Tong X, Patel AS, Kim E, et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42(3):413–428.e7.

Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25(5):590–604.

Kim EK, Park JM, Lim S, et al. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J Biol Chem. 2011;286(27):24036–24045.

Buensuceso A, Ramos-Valdes Y, DiMattia GE, Shepherd TG. AMPK-independent LKB1 activity is required for efficient epithelial ovarian cancer metastasis. Mol Cancer Res. 2020;18(3):488–500.

Volik S, Lebedev Y, Nikolaev L, et al. Mapping of transcribed sequences on human chromosome 19. DNA Sequence. 1995;6(1):13–26.

Ashworth LK, Batzer MA, Brandriff B, et al. An integrated metric physical map of human chromosome 19. Nat Genet. 1995;11(4):422–427.

Yoneda Y. How proteins are transported from cytoplasm to the nucleus. J Biochem. 1997;121(5):811–817.

Smith DP, Spicer J, Smith A, Swift S, Ashworth A. The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum Mol Genet. 1999;8(8):1479–1485.

Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001–3007.

Sun R, Li J, Wang B, et al. Liver kinase B1 promoter CpG island methylation is related to lung cancer and smoking. Int J Clin Exp Med. 2015;8(8):14070–14074.

Zheng F, Yuan X, Chen E, Ye Y, Li X, Dai Y. Methylation of STK11 promoter is a risk factor for tumor stage and survival in clear cell renal cell carcinoma. Oncol Lett. 2017;14(3):3065–3070.

Li T, Lin W, Zhao Y, Zhu J, Sun T, Ren L. Distinct promoter methylation patterns of LKB1 in the hamartomatous polyps of Peutz-Jeghers syndrome and its potential in gastrointestinal malignancy prediction. Orphanet J Rare Dis. 2020;15(1):208.

Zhang W, Li X, Song G, Luo D. Prognostic significance of LKB1 promoter methylation in cutaneous malignant melanoma. Oncol Lett. 2017;14(2):2075–2080.

Koenig MJ, Agana BA, Kaufman JM, et al. STK11/LKB1 loss of function is associated with global DNA hypomethylation and S-adenosyl-methionine depletion in human lung adenocarcinoma. Cancer Res. 2021;81(16):4194–4204.

Borzi C, Ganzinelli M, Caiola E, et al. LKB1 down-modulation by miR-17 identifies patients with NSCLC having worse prognosis eligible for energy-stress-based treatments. J Thorac Oncol. 2021;16(8):1298–1311.

Boldrini L, Giordano M, Lucchi M, Melfi F, Fontanini G. Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. Biomed Rep. 2018;9(3):198–205.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer. Oncotarget. 2015;6(30):29947–29962.

Figueroa-González G, Carrillo-Hernández JF, Perez-Rodriguez I, et al. Negative regulation of serine threonine kinase 11 (STK11) through miR-100 in head and neck cancer. Genes. 2020;11(9):1058.

Zhou Y, Zhang Y, Li Y, et al. MicroRNA-106a-5p promotes the proliferation, autophagy and migration of lung adenocarcinoma cells by targeting LKB1/AMPK. Exp Ther Med. 2021;22(6):1422.

Fang X, Shen F, Lechauve C, et al. miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia. Haematologica. 2018;103(3):406–416.

Chen H, Untiveros GM, McKee LA, et al. Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25. PLoS One. 2012;7(7):e41574.

Godlewski J, Nowicki MO, Bronisz A, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620–632.

Izreig S, Gariepy A, Kaymak I, et al. Repression of LKB1 by miR-17~92 sensitizes MYC-dependent lymphoma to biguanide treatment. Cell Rep Med. 2020;1(2):100014.

Islam MJ, Khan AM, Parves MR, Hossain MN, Halim MA. Prediction of deleterious non-synonymous SNPs of human STK11 gene by combining algorithms, molecular docking, and molecular dynamics simulation. Sci Rep. 2019;9:16426.

Radenbaugh AJ, Ma S, Ewing A, et al. RADIA: RNA and DNA integrated analysis for somatic mutation detection. PLoS One. 2014;9(11):e111516.

Ishqi HM, Sarwar T, Husain MA, Rehman SU, Tabish M. Differentially expressed novel alternatively spliced transcript variant of tumor suppressor Stk11 gene in mouse. Gene. 2018;668:146–154.

Lützner N, De-Castro Arce J, Rösl F. Gene expression of the tumour suppressor LKB1 is mediated by Sp1, NF-Y and FOXO transcription factors. PLoS One. 2012;7(3):e32590.

Rabbani B, Mahdieh N, Haghi Ashtiani MT, Setoodeh A, Rabbani A. In silico structural, functional and pathogenicity evaluation of a novel mutation: an overview of HSD3B2 gene mutations. Gene. 2012;503(2):215–221.

Lim W, Hearle N, Shah B, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer. 2003;89(2):308–313.

Mehenni H, Gehrig C, Nezu J, et al. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet. 1998;63(6):1641–1650.

Newton SM, Igo JD, Scott DC, Klebba PE. Effect of loop deletions on the binding and transport of ferric enterobactin by FepA. Mol Microbiol. 1999;32(6):1153–1165.

Batey S, Nickson AA, Clarke J. Studying the folding of multidomain proteins. HFSP J. 2008;2(6):365–377.

Collins SP, Reoma JL, Gamm DM, Uhler MD. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J. 2000;345(Pt 3):673–680.

Denison FC, Hiscock NJ, Carling D, Woods A. Characterization of an alternative splice variant of LKB1. J Biol Chem. 2009;284(1):67–76.

Towler MC, Fogarty S, Hawley SA, et al. A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis. Biochem J. 2008;416(1):1–14.

Couderc JL, Richard G, Vachias C, Mirouse V. Drosophila LKB1 is required for the assembly of the polarized actin structure that allows spermatid individualization. PLoS One. 2017;12(8):e0182279.

Laderian B, Mundi P, Fojo T, Bates SE. Emerging therapeutic implications of STK11 mutation: case series. Oncol. 2020;25(9):733–737.

Kong F, Wang M, Huang X, et al. Differential regulation of spermatogenic process by Lkb1 isoforms in mouse testis. Cell Death Dis. 2017;8(10):e3121.

Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, et al. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget. 2017;8(14):23831–23840.

Rogers ZN, McFarland CD, Winters IP, et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet. 2018;50(4):483–486.

Momcilovic M, Shackelford DB. Targeting LKB1 in cancer - exposing and exploiting vulnerabilities. Br J Cancer. 2015;113(4):574–584.

Zhao N, Wu H, Li P, et al. A novel pathogenic splice site variation in STK11 gene results in Peutz-Jeghers syndrome. Mol Genet Genomic Med. 2021;9(8):e1729.

Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 2014;42(22):13534–13544.

Tiainen M, Ylikorkala A, Mäkelä TP. Growth suppression by Lkb1 is mediated by a G₁ cell cycle arrest. Proc Natl Acad Sci U S A. 1999;96(16):9248–9251.

Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003;22(12):3062–3072.

Buchet-Poyau K, Mehenni H, Radhakrishna U, Antonarakis SE. Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. Cytogenet Genome Res. 2002;97(3–4):171–178.

de Leng WW, Keller JJ, Luiten S, et al. STRAD in Peutz-Jeghers syndrome and sporadic cancers. J Clin Pathol. 2005;58(10):1091–1095.

Marignani PA, Scott KD, Bagnulo R, et al. Novel splice isoforms of STRADalpha differentially affect LKB1 activity, complex assembly and subcellular localization. Cancer Biol Ther. 2007;6(10):1627–1631.

Dorfman J, Macara IG. STRADα regulates LKB1 localization by blocking access to importin-α, and by association with Crm1 and exportin-7. MBoC. 2008;19(4):1614–1626.

Qing T, Liu J, Liu F, Mitchell DC, Beresis RT, Gordan JD. Methods to assess small molecule allosteric modulators of the STRAD pseudokinase. Methods Enzymol. 2022;667:427–453.

Eggers CM, Kline ER, Zhong D, Zhou W, Marcus AI. STE20-related kinase adaptor protein α (STRADα) regulates cell polarity and invasion through PAK1 signaling in LKB1-null cells. J Biol Chem. 2012;287(22):18758–18768.

Duivenvoorden WC, Beatty LK, Lhotak S, et al. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer. 2013;108(2):327–333.

Contreras CM, Gurumurthy S, Haynie JM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 2008;68(3):759–766.

Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905.

Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24(3):2643.

Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.

Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002;62(13):3659–3662.

Mung KL, Eccleshall WB, Santio NM, Rivero-Müller A, Koskinen PJ. PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1. Cell Commun Signal. 2021;19(1):68.

Rao F, Xu J, Fu C, et al. Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proc Natl Acad Sci U S A. 2015;112(6):1773–1778.

Göransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem. 2007;282(45):32549–32560.

Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene. 2015;34(28):3627–3639.

Hirose S, Murakami N, Takahashi K, et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol Oncol. 2020;156(1):203–210.

Selenica P, Alemar B, Matrai C, et al. Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Mod Pathol. 2021;34(6):1213–1225.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, et al. LKB1/STK11 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value. Lung Cancer. 2017;112:62–68.

Shire NJ, Klein AB, Golozar A, et al. STK11(LKB1) mutations in metastatic NSCLC: prognostic value in the real world. PLoS One. 2020;15(9):e0238358.

Rosellini P, Amintas S, Caumont C, et al. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. Eur J Cancer. 2022;172:85–95.

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–10812.

Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-ζ is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008;117(7):952–962.

Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care. 2010;33(2):322–326.

Hui T, Shang C, Yang L, Wang M, Li R, Song Z. Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus. Sci Rep. 2021;11(1):10034.

Meng F, Song L, Wang W. Metformin improves overall survival of colorectal cancer patients with diabetes: a meta-analysis. J Diabetes Res. 2017;2017:5063239.

Zeng S, Gan HX, Xu JX, Liu JY. Metformin improves survival in lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Med Clínica Engl Ed. 2019;152(8):291–297.

van Den Neste E, Cazin B, Janssens A, et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase Ⅰ/Ⅱ study. Cancer Chemother Pharmacol. 2013;71(3):581–591.

Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012;5(3):355–364.

Chen YH, Yang SF, Yang CK, et al. Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. Mol Med Rep. 2021;23(1):88.

Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016;2(5):241–251.

Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol. 1991;31(4):342–347.

Cluzeau T, Furstoss N, Savy C, et al. Acadesine circumvents azacitidine resistance in myelodysplastic syndrome and acute myeloid leukemia. Int J Mol Sci. 2019;21(1):164.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.

Sun Y, Connors KE, Yang DQ. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem. 2007;306(1–2):239–245.

Caso R, Sanchez-Vega F, Tan KS, et al. The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol. 2020;15(12):1844–1856.

Jee J, Lebow ES, Yeh R, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022;28(11):2353–2363.

Giraldo NA, Drill E, Satravada BA, et al. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022;28(24):5359–5367.

Elkin R, Oh JH, Liu YL, et al. Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. NPJ Genom Med. 2021;6(1):99.

Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–337.e10.

Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916–1927.

Sihag S, Nussenzweig SC, Walch HS, et al. The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma. Clin Cancer Res. 2022;28(12):2669–2678.

Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33(1):125–136.e3.

Nacev BA, Sanchez-Vega F, Smith SA, et al. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat Commun. 2022;13(1):3405.

Ho AS, Ochoa A, Jayakumaran G, et al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Investig. 2019;129(10):4276–4289.

Zulato E, Ciccarese F, Agnusdei V, et al. LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiation. Biochem Pharmacol. 2018;156:479–490.

Inge LJ, Friel JM, Richer AL, et al. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress. Cancer Lett. 2014;352(2):187–195.

Bonanno L, de Paoli A, Zulato E, et al. LKB1 expression correlates with increased survival in patients with advanced non-small cell lung cancer treated with chemotherapy and bevacizumab. Clin Cancer Res. 2017;23(13):3316–3324.

Rho SB, Byun HJ, Kim BR, Lee CH. Knockdown of LKB1 sensitizes endometrial cancer cells via AMPK activation. Biomol Ther (Seoul). 2021;29(6):650–657.

Shameem M, Bagherpoor AJ, Nakhi A, Dosa P, Georg G, Kassie F. Mitochondria-targeted metformin (mitomet) inhibits lung cancer in cellular models and in mice by enhancing the generation of reactive oxygen species. Mol Carcinog. 2023;62(11):1619–1629.

Whang YM, Park SI, Trenary IA, et al. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene. 2016;35(7):856–866.

Long LL, Ma SC, Guo ZQ, et al. PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer. Cancer Res. 2023;83(4):568–581.

Caiola E, Iezzi A, Tomanelli M, et al. LKB1 deficiency renders NSCLC cells sensitive to ERK inhibitors. J Thorac Oncol. 2020;15(3):360–370.

Trapp EK, Majunke L, Zill B, et al. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. Mol Oncol. 2017;11(11):1508–1526.

Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485(7400):661–665.

Jiang S, Wang Y, Luo L, et al. AMP-activated protein kinase regulates cancer cell growth and metabolism via nuclear and mitochondria events. J Cell Mol Med. 2019;23(6):3951–3961.

Li W, Wong CC, Zhang X, et al. CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis. Oncogene. 2018;37(50):6383–6398.

Zhang M, Deng YN, Zhang JY, et al. SIRT3 protects rotenone-induced injury in SH-SY₅Y cells by promoting autophagy through the LKB1-AMPK-mTOR pathway. Aging Dis. 2018;9(2):273–286.

Takahashi Y, Coppola D, Matsushita N, et al. Bif-1 interacts with beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007;9(10):1142–1151.

Trelford CB, di Guglielmo GM. Molecular mechanisms of mammalian autophagy. Biochem J. 2021;478(18):3395–3421.

Trelford CB, di Guglielmo GM. Autophagy regulates transforming growth factor β signaling and receptor trafficking. Biochim Biophys Acta Mol Cell Res. 2022;1869(9):119284.

Cai Y, Cai J, Ma Q, et al. Chloroquine affects autophagy to achieve an anticancer effect in EC109 esophageal carcinoma cells in vitro. Oncol Lett. 2018;15(1):1143–1148.

Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med Lond Engl. 2017;17(6):545–551.